13.02.2025 • News

Gevo and Axens Broaden their SAF Partnership

US clean technology company Gevo and French technology provider Axens have formed a new strategic alliance to accelerate development and commercialization of sustainable aviation fuel (SAF) using the ethanol-to-jet (ETJ) pathway.

“Today, Axens and Gevo are delivering the most cost-effective, commercially proven SAF technology with Axens Jetanol and Gevo’s process and business system,” said Paul Bloom, Gevo’s chief business officer. “By expanding our partnership to accelerate the commercialization of Gevo’s ETO technology, we’re combining our industry expertise to further reduce costs and create SAF that is competitive with fossil fuels while capitalizing on the growing carbon market.”

Building on their previous commercial cooperation, Axens and Gevo will partner with IFP Energies Nouvelles (IFPEN), a public research, innovation and training organization, on the final development and commercial deployment of Gevo’s next-generation ethanol-to-olefins (ETO) process for fuel applications that are expected to achieve zero carbon intensity or better. According to Gevo, the technology produces light olefins from ethanol, which can then be converted to transportation fuels utilizing commercially proven oligomerization and hydrogenation technologies.

Provided the technology development is completed successfully, Gevo is expected to lead deployment of its ETO technology in North America, and Axens would provide process licensing, catalyst, equipment, and engineering services globally.

© Shutterstock / IM_photo
© Shutterstock / IM_photo

Quentin Debuisschert, CEO of Axens, commented: “The combination of Gevo market know-how and capacity of project development with Axens best-in-class technology, Jetanol, is expected to allow a fast acceptance and adoption of the ETJ Pathway. The future ETO technology commercialization will keep Axens and Gevo on the cutting edge of the ETJ pathway by offering end-users and project developers the possibility to select the most attractive technology for their situation.”

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read